Jeffrey H. Chen

3.3k citations

7 papers · 1.6k indexed · 3 hit papers · h-index 6

Molecular Biology top 10%
Oncology top 5%
Organic Chemistry top 5%
Pulmonary and Respiratory Medicine top 10%
Cancer Research top 10%

Co-authors: Brion W. Murray Robert S. Kania Michele McTigue James Solowiej Yali Deng Anjali Babbar Pingda RenTess Ely
Topics: PI3K/AKT/mTOR signaling in cancer (4 papers)Renal cell carcinoma treatment (2 papers)Angiogenesis and VEGF in Cancer (2 papers)
Cited by: Oncology Molecular Biology Toxicology
Journals: Proceedings of the National Academy of Sciences Cancer Research Clinical Cancer Research
Partner nations: United States China

In The Last Decade

Jeffrey H. Chen

7 papers receiving 1.5k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Selective Inhibition of Oncogenic KRAS Output with Small Molecules Targeting the Inactive State

2016 530 citations Matthew P. Patricelli, Matthew R. Janes et al. Cancer Discovery profile →
Nonclinical Antiangiogenesis and Antitumor Activities of Axitinib (AG-013736), an Oral, Potent, and Selective Inhibitor of Vascular Endothelial Growth Factor Receptor Tyrosine Kinases 1, 2, 3

2008 515 citations Dana D. Hu‐Lowe, Helen Y. Zou et al. Clinical Cancer Research profile →
Molecular conformations, interactions, and properties associated with drug efficiency and clinical performance among VEGFR TK inhibitors

2012 451 citations Michele McTigue, Brion W. Murray et al. Proceedings of the National Academy of Sciences profile →

Peers

Countries citing papers authored by Jeffrey H. Chen

Since Specialization

Citations

This map shows the geographic impact of Jeffrey H. Chen's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Jeffrey H. Chen with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Jeffrey H. Chen more than expected).

Fields of papers citing papers by Jeffrey H. Chen

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Jeffrey H. Chen. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Jeffrey H. Chen. The network helps show where Jeffrey H. Chen may publish in the future.

Co-authorship network of co-authors of Jeffrey H. Chen

This figure shows the co-authorship network connecting the top 25 collaborators of Jeffrey H. Chen. A scholar is included among the top collaborators of Jeffrey H. Chen based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Jeffrey H. Chen. Jeffrey H. Chen is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

7 of 7 papers shown

#	Work	Indexed citations
1	Selective Inhibition of Oncogenic KRAS Output with Small Molecules Targeting the Inactive Statebreakdown → 2016 ·Cancer Discovery ·Matthew P. Patricelli,Matthew R. Janes,Lian‐Sheng Li,Rasmus Hansen,Ulf Peters,Linda Kessler,Yuching Chen,Jeff Kucharski,Jun Feng,Tess Ely,Jeffrey H. Chen,Sarah J. Firdaus,Anjali Babbar,Pingda Ren,Yi Liu	530
2	Substrate-Specific Conformational Regulation of the Receptor Tyrosine Kinase VEGFR2 Catalytic Domain 2013 ·ACS Chemical Biology ·James Solowiej,Jeffrey H. Chen,Helen Y. Zou,Stephan K. Grant,Brion W. Murray	4
3	Molecular conformations, interactions, and properties associated with drug efficiency and clinical performance among VEGFR TK inhibitorsbreakdown → 2012 ·Proceedings of the National Academy of Sciences ·Michele McTigue,Brion W. Murray,Jeffrey H. Chen,Yali Deng,James Solowiej,Robert S. Kania	451
4	Highly Selective and Potent Thiophenes as PI3K Inhibitors with Oral Antitumor Activity 2011 ·ACS Medicinal Chemistry Letters ·(unknown),JinJiang Zhu,Graham L. Smith,Min-Jean Yin,Simon Bailey,Jeffrey H. Chen,Qiyue Hu,Qinhua Huang,Chunze Li,(unknown),Matthew A. Marx,Genevieve Paderes,Paul Richardson,Neal W. Sach,Marlena Walls,Peter A. Wells,Aihua Zou	23
5	Dual Functional Monoclonal Antibody PF-04605412 Targets Integrin α5β1 and Elicits Potent Antibody-Dependent Cellular Cytotoxicity 2010 ·Cancer Research ·Gang Li,Lianglin Zhang,Enhong Chen,Jianying Wang,Xin Jiang,Jeffrey H. Chen,Grant Wickman,Karin Amundson,Simon Bergqvist,James Zobel,(unknown),Sangita M. Baxi,Steven L. Bender,Gerald F. Casperson,Dana D. Hu‐Lowe	20
6	Quinazolines with intra-molecular hydrogen bonding scaffold (iMHBS) as PI3K/mTOR dual inhibitors 2010 ·Bioorganic & Medicinal Chemistry Letters ·Kevin K.‐C. Liu,Xiao‐Jun Huang,Shubha Bagrodia,Jeffrey H. Chen,S.E. Greasley,Hengmiao Cheng,Shaoxian Sun,(unknown),Caroline Rodgers,Kristina Rafidi,Aihua Zou,(unknown),Shengyong Yan	26
7	Nonclinical Antiangiogenesis and Antitumor Activities of Axitinib (AG-013736), an Oral, Potent, and Selective Inhibitor of Vascular Endothelial Growth Factor Receptor Tyrosine Kinases 1, 2, 3breakdown → 2008 ·Clinical Cancer Research ·Dana D. Hu‐Lowe,Helen Y. Zou,Maren L. Grazzini,Max Hallin,Grant Wickman,Karin Amundson,Jeffrey H. Chen,David A. Rewolinski,Shinji Yamazaki,Xinglin Wu,Michele McTigue,Brion W. Murray,Robert S. Kania,Patrick M. O’Connor,David R. Shalinsky,Steve Bender	515

About Jeffrey H. Chen

Jeffrey H. Chen is a scholar working on Immunology and Allergy, Molecular Biology and Organic Chemistry, having authored 7 papers that have together received 1.6k indexed citations. Recurring topics across this work include PI3K/AKT/mTOR signaling in cancer (4 papers), Renal cell carcinoma treatment (2 papers) and Angiogenesis and VEGF in Cancer (2 papers). The work is most often cited by research in Oncology (520 citations), Molecular Biology (1.0k citations) and Toxicology (49 citations). Jeffrey H. Chen has collaborated with scholars based in United States and China. Frequent co-authors include Brion W. Murray, Robert S. Kania, Michele McTigue, James Solowiej, Yali Deng, Anjali Babbar, Pingda Ren, Tess Ely, Matthew R. Janes and Lian‐Sheng Li. Their work appears in journals such as Proceedings of the National Academy of Sciences, Cancer Research and Clinical Cancer Research.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact